10.15
+0.7(+7.41%)
Currency In USD
| Previous Close | 9.45 |
| Open | 9.51 |
| Day High | 10.26 |
| Day Low | 9.01 |
| 52-Week High | 13.5 |
| 52-Week Low | 2.28 |
| Volume | 53,764 |
| Average Volume | 120,923 |
| Market Cap | 94.44M |
| PE | -2.95 |
| EPS | -3.44 |
| Moving Average 50 Days | 8.54 |
| Moving Average 200 Days | 5.08 |
| Change | 0.7 |
If you invested $1000 in Clene Inc. (CLNN) since IPO date, it would be worth $52.05 as of November 26, 2025 at a share price of $10.15. Whereas If you bought $1000 worth of Clene Inc. (CLNN) shares 5 years ago, it would be worth $46.65 as of November 26, 2025 at a share price of $10.15.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference
GlobeNewswire Inc.
Nov 20, 2025 1:00 PM GMT
SALT LAKE CITY, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondria
Clene to Participate in a Panel Discussion at the Maxim Growth Summit
GlobeNewswire Inc.
Oct 15, 2025 12:30 PM GMT
SALT LAKE CITY, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondria
Clene Presents New Clinical Data at ECTRIMS 2025 Meeting Demonstrating CNM-Au8® Improves Brain Energy Metabolism in Multiple Sclerosis Patients
GlobeNewswire Inc.
Sep 25, 2025 12:00 PM GMT
Late-breaking clinical data presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis Across non-active progressive MS (primary progressive and secondary progressive MS), relapsing MS, and Parkinson’s d